Clinical Chemistry AACC Online Job Center spacer gif
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2007.088252v1, 2007; 10.1373/clinchem.2007.088252
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.088252v1
53/6/1099    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snozek, C. L.H.
Right arrow Articles by Katzmann, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snozek, C. L.H.
Right arrow Articles by Katzmann, J. A.

Received on February 28, 2007
Accepted on March 29, 2007

Hematology

Comparison of Bromcresol Green and Agarose Protein Electrophoresis for Quantitation of Serum Albumin in Multiple Myeloma

Christine L.H. Snozek 1, Amy K. Saenger 1, Philip R. Greipp 2, Sandra C. Bryant 3, Robert A. Kyle 2, S. Vincent Rajkumar 2, Jerry A. Katzmann 1*

1 Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
2 Department of Internal Medicine/Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN
3 Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN

* To whom correspondence should be addressed. E-mail: katzmann{at}mayo.edu.

Background: The International Staging System for multiple myeloma has increased the importance of accurate measurement of serum albumin. Two common albumin assays, bromcresol green (BCG) and agarose gel protein electrophoresis (PEL), frequently yield discordant results, creating confusion regarding which assay is superior for use in myeloma.

Methods: We measured albumin by BCG on a Roche Modular system, by PEL with a Helena SPIFE SPE Vis agarose gel, and by immunonephelometry performed on a Dade Behring BNII nephelometer. BCG and PEL were used to measure albumin in 5777 patient samples, and all 3 methods were used in an additional 252 samples. The clinical impact was assessed on 698 myeloma patient samples.

Results: For sera with zero/low monoclonal immunoglobulin protein (M)-spike (0 to <15 g/L), results for both BCG and PEL correlated well to nephelometry, although median PEL results were 8 g/L lower than corresponding BCG measurements. Correlation between PEL and nephelometry or BCG diminished with increasing M-spike, with PEL eventually overestimating albumin compared with both other assays. IgG and IgA M-spikes showed significantly different effects on albumin discordance. For 35% of myeloma patients, discrepancy between BCG and PEL had a potentially clinically significant effect on staging, but no difference in group survival was found.

Conclusions: Both BCG and PEL correlate well to nephelometry in sera with zero/low M-spikes. In the presence of larger M-spikes, PEL correlates poorly to nephelometry or BCG, whereas BCG compares well with nephelometry regardless of M-spike. Thus, albumin measurement can be performed reliably in myeloma patient sera by use of inexpensive, automated BCG assays.




spacer gif
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.